Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus

Journal of Pharmacy Practice

Volumn 30, Issue 5, 2017, Pages 549-556

  Bellucci, Pamela Natalia ^a   González Bagnes, María Florencia ^a   Di Girolamo, Guillermo ^b   González, Claudio Daniel ^a  

^a CEMIC   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

COX inhibition; diabetes; inflammation; NSAIDs; salsalate

Indexed keywords

ANAKINRA; HEMOGLOBIN A1C; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SALSALATE; ZILEUTON; CYCLOOXYGENASE 2 INHIBITOR;

DIABETIC MICROANGIOPATHY; DIZZINESS; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEPATITIS; HUMAN; HYPOGLYCEMIA; INSULIN CLEARANCE; INSULIN RESISTANCE; LIVER RESECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TINNITUS; ANIMAL; BLOOD; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE;

EID: 85014934171     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190016649551     Document Type: Review

References (51)

1. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002; 99 (21): 13926-13931.
2. Rao P, Knaus EE,. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008; 11 (2): 81s-110s.
3. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006; 17 (1): 4-12.
4. King GL,. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008; 79 (8 suppl): 1527-1534.
5. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353 (9165): 1649-1652.
6. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286 (3): 327-334.
7. Donath MY, Dalmas É Sauter NS, et al. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 2013; 17 (6): 860-872.
8. Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised antiinterleukin 6 receptor antibody tocilizumab. Ann Rheum Dis. 2011; 70 (6): 1164-1165.
9. Esser N, Paquot N, Scheen AJ,. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015; 24 (3): 283-307.
10. Kotas ME, Gorecki MC, Gillum MP,. Sirtuin-1 is a nutrient-dependent modulator of inflammation. Adipocyte. 2013; 2 (2): 113-118.
11. Hameed I, Masoodi SR, Mir SA, et al. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabetes. 2015; 6 (4): 598-612.
12. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009; 32 (9): 1663-1668.
13. González CD, Lee MS, Marchetti P, et al. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy. 2011; 7 (1): 2-11.
14. Kitamura T,. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol. 2013; 9 (10): 615-623.
15. Mothe-Satney I, Filloux C, Amghar H, et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012; 61 (9): 2311-2319.
16. Neels JG,. A role for 5-lipoxygenase products in obesity-associated inflammation and insulin resistance. Adipocyte. 2013; 2 (4): 262-265.
17. Di Girolamo G, Farina M, Riberio ML, et al. Effects of cyclooxygenase inhibitor pretreatment on nitric oxide production, nNOS and iNOS expression in rat cerebellum. Br J Pharmacol. 2003; 139 (6): 1164-1170.
18. Di Girolamo G, Franchi A, De Los Santos AR, et al. Acción de los antiinflamatorios no esteroideos sobre la actividad de la lipooxigenasa y la ciclooxigenasa colónica de pacientes con neoplasia de colon. Medicina (B Aires). 2001; 61 (5 pt 1): 566-572.
19. Kramer EH, Sassetti B, Kaminker AJ, et al. Effects of lysine clonixinate on platelet function. Comparison with other non-steroidal anti-inflammatory agents. Medicina (B Aires). 2001; 61 (3): 301-307.
20. Franchi A, Di Girolamo G, Farina M, et al. In vivo and in vitro effects of lysine clonixinate on nitric oxide synthase in LPS-treated and untreated rat lung preparations. Nitric Oxide. 2001; 5 (2): 150-157.
21. Fleischman A, Shoelson SE, Bernier R, et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008; 31 (2): 289-294.
22. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double blind placebo-controlled study. Diabetologia. 2009; 52 (3): 385-393.
23. Goldfine AB, Fonseca V, Jablonski KA, et al. Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013; 159 (1): 1-12.
24. Faghihimani E, Aminorroaya A, Rezvanian H, et al. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2013; 50 (4): 537-543.
25. Faghihimani E, Aminorroaya A, Rezvanian H, et al. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract. 2012; 18 (6): 826-833.
26. Kim SH, Liu A, Ariel D, et al. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study. Diabetes Care. 2014; 37 (7): 1944-1950.
27. Barzilay JI, Jablonski KA, Fonseca V, et al. TINSAL-T2D Research Consortium. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care. 2014; 37 (4): 1083-1091.
28. Goldfine AB, Buck JS, Desouza C, et al.TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes-Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care. 2013; 36 (12): 4132-4139.
29. Fang F, Lu Y, Ma DL, et al. A meta-analysis of salicylates for type 2 diabetes mellitus. J Huazhong Univ Sci Technolog Med Sci. 2013; 33 (1): 1-14.
30. Penesova A, Koska J, Ortega E, et al. Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes. Diabetes Obes Metab. 2015; 17 (6): 608-612.
31. Alderete TL, Sattler FR, Richey JM, et al. Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese Hispanics. Diabetes Obes Metab. 2015; 17 (6): 608-612.
32. Motawi TM, Bustanji Y, El-Maraghy SA, et al. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol. 2013; 27 (9): 425-436.
33. Sung KC, Kim SH,. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011; 96 (4): 1093-1097.
34. Targher G, Byrne CD,. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013; 98 (2): 483-495.
35. Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation. J Hepatol. 2013; 59 (3): 583-594.
36. Chai W, Liu J, Jahn LA, et al. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011; 34 (7): 1634-1638.
37. Nixon M, Wake DJ, Livingstone DE, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012; 61 (4): 790-796.
38. Davis SN, Granner DK,. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001: 1679-1714.
39. Roberts LJ, Morrow JD,. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001: 687-731.
40. El-Serag HB, Hampel H, Javadi F,. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4 (3): 369-380.
41. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012; 308 (18): 1906-1914.
42. Yeh CC, Lin JT, Jeng LB, et al. Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study. Ann Surg. 2015; 261 (3): 521-526.
43. Sethi A, Parmar HS, Kumar A,. The effect of aspirin on atherogenic diet-induced diabetes mellitus. Basic Clin Pharmacol Toxicol. 2011; 108 (6): 371-377.
44. Sun X, Han F, Yi J, et al. Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci. 2011; 26 (6): 765-770.
45. Murali G, Milne GL, Webb CD, et al. Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice. J Lipid Res. 2012; 53 (10): 2186-2197.
46. Tian F, Zhang YJ, Li Y, et al. Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression. PLoS One. 2014; 9 (1): e83819.
47. Bahde R, Kapoor S, Gupta S,. Nonselective inhibition of prostaglandin-endoperoxide synthases by naproxen ameliorates acute or chronic liver injury in animals. Exp Mol Pathol. 2014; 96 (1): 27-35.
48. Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012; 104 (23): 1808-1814.
49. Goldfine AB, Fonseca V, Jablonski KA, et al.TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010; 152 (6): 346-357.
50. Huang HL, Liu CT, Chou MC, et al. Noni (Morinda citrifolia L.) Fruit Extracts Improve colon microflora and exert anti-inflammatory activities in Caco-2 cells. J Med Food. 2015; 18 (6): 663-676.
51. Hu P, Thinschmidt JS, Caballero S, et al. Loss of survival factors and activation of inflammatory cascades in brain sympathetic centers in type 1 diabetic mice. Am J Physiol Endocrinol Metab. 2015; 308 (8): e688-e698. doi:10.1152/ajpendo.00504.2014.